Mykronor (Noradrenaline Tartrate)

Noradrenaline tartrate, the active ingredient in Mykronor, is a sympathomimetic vasopressor presented as a sterile solution for injection for intravenous use. It is employed to raise blood pressure in acute hypotensive episodes, including septic, cardiogenic, and postoperative shock, under the supervision of qualified clinicians in hospital settings.

GNH USA supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU GMP standards and provides cold‑chain logistics where required, ensuring product integrity from manufacture to end‑user.

Mykronor, a sympathomimetic vasopressor, is used in conditions characterized by severe hypotension and circulatory shock.

- Acute hypotension: restores systemic blood pressure to maintain organ perfusion. - Septic shock: supports vascular tone when endogenous catecholamines are insufficient. - Cardiogenic shock: augments cardiac output by increasing afterload and coronary perfusion pressure. - Post‑operative hypotension: stabilises hemodynamics during the immediate recovery period.

Adverse reactions may occur with intravenous noradrenaline administration.

Common Side Effects: - Tachycardia: increased heart rate due to beta‑1 stimulation. - Headache: result of rapid blood pressure elevation. - Anxiety or restlessness: central nervous system response to catecholamine surge. - Peripheral ischemia: reduced blood flow to extremities from intense vasoconstriction.

Serious or Rare Side Effects: - Myocardial ischemia: excessive coronary vasoconstriction. - Severe hypertension: dangerously high arterial pressure. - Life‑threatening arrhythmias: ventricular tachycardia or fibrillation. - Tissue necrosis at the infusion site: extravasation of the vasopressor.

Careful monitoring and specific precautions are required when using Mykronor.

- Dose titration: adjust infusion rate to achieve target mean arterial pressure. - Cardiovascular monitoring: continuous ECG and invasive blood pressure monitoring are essential. - Extravasation risk: inspect IV site frequently and avoid infiltration. - Contraindications: do not use in patients with known hypersensitivity to noradrenaline. - Pregnancy and lactation: administer only if potential benefits justify potential risks (category unknown). - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: additive pressor effects. - Beta‑blockers: may blunt desired cardiac response. - General anesthetics that depress sympathetic tone: may reduce efficacy. - Potent vasodilators (e.g., nitroprusside): may counteract pressor action.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive episodes when noradrenaline is tapered. - Calcium channel blockers: potential additive cardiovascular effects. - Diuretics: volume depletion can alter response. - Other vasopressors: overlapping mechanisms may increase risk of excessive vasoconstriction. - Sedatives and opioids: may mask signs of hypertension or tachycardia.